Newsroom

Vanity Metrics & Black Boxes ≠Therapeutics

Lani Nguyen 9/27/23 Lani Nguyen 9/27/23

Vanity Metrics & Black Boxes ≠Therapeutics

Read More

The Tripledemic: AI-Drug Discovery and the Quest for a Pan-Antiviral Drug

Lani Nguyen 12/13/22 Lani Nguyen 12/13/22

The Tripledemic: AI-Drug Discovery and the Quest for a Pan-Antiviral Drug

Read More

Model Medicines Selected to Participate at the 2022 BioPharm America Event in Boston, Following Submission of a Pre-IND Briefing Document and Meeting Request to the FDA

Lani Nguyen 9/28/22 Lani Nguyen 9/28/22

Model Medicines Selected to Participate at the 2022 BioPharm America Event in Boston, Following Submission of a Pre-IND Briefing Document and Meeting Request to the FDA

September 28–29, 2022 ・Boston, MA

Read More

Model Medicines Selected to Present at the 2022 BIO International Convention, Following Recent Submission of a Pre-IND Briefing Document and Meeting Request to the FDA

Lani Nguyen 6/1/22 Lani Nguyen 6/1/22

Model Medicines Selected to Present at the 2022 BIO International Convention, Following Recent Submission of a Pre-IND Briefing Document and Meeting Request to the FDA

June 13-16 2022 ・San Diego, CA

Read More

MDL-001 Demonstrates Potential Best-In-Class Combination of Viral Load Reduction, Symptom Reduction, Activity Against SARS-CoV-2 Variants, and Pan Antiviral Activity

Lani Nguyen 5/17/22 Lani Nguyen 5/17/22

MDL-001 Demonstrates Potential Best-In-Class Combination of Viral Load Reduction, Symptom Reduction, Activity Against SARS-CoV-2 Variants, and Pan Antiviral Activity

Read More

Model Medicines to Participate in the Berenberg Discover AI Seminar 2022

Lani Nguyen 4/25/22 Lani Nguyen 4/25/22

Model Medicines to Participate in the Berenberg Discover AI Seminar 2022

May 19 2022 ・San Francisco, CA

Read More

American Chemical Society recognizes Model Medicines’ MDL-001 among next generation of COVID-19 antivirals

Lani Nguyen 3/28/22 Lani Nguyen 3/28/22

American Chemical Society recognizes Model Medicines’ MDL-001 among next generation of COVID-19 antivirals

Read More

Model Medicines to Participate in the Truist Securities Life Sciences AI Symposium

Lani Nguyen 3/1/22 Lani Nguyen 3/1/22

Model Medicines to Participate in the Truist Securities Life Sciences AI Symposium

March 1 2022 ・Virtual

Read More

Model Medicines' Oral Anti-COVID-19 Drug Candidate MDL-001 Found to Significantly Reduce Viral Load in Lungs; Accepted into NIH’s Antiviral Program for Pandemics (APP)

Lani Nguyen 2/8/22 Lani Nguyen 2/8/22

Model Medicines' Oral Anti-COVID-19 Drug Candidate MDL-001 Found to Significantly Reduce Viral Load in Lungs; Accepted into NIH’s Antiviral Program for Pandemics (APP)

Read More

Model Medicines announces preclinical data in study of orally available lead therapeutic against COVID-19, in partnership with Scripps Research and Mount Sinai

Lani Nguyen 9/22/21 Lani Nguyen 9/22/21

Model Medicines announces preclinical data in study of orally available lead therapeutic against COVID-19, in partnership with Scripps Research and Mount Sinai

Read More

Model Medicines’ CHEMprint™ AI/ML drug discovery platform successfully identified multiple drug candidates that were found to be active against SARS-CoV-2 replication in a live virus study in a human cell line at a hit rate of over 14%.

“AI and ML models... can significantly improve the efficacy of drug discovery.”

Arnab Chatterjee, Ph.D
Calibr at Scripps Research

“We are very pleased with the demonstrated potent antiviral activity of MDL-001.”

Davey Smith, MDUC
San Diego Health

“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”

Sumit Chanda, Ph.D.
Sanford Burnham Prebys

“...a game-changer in the global fight against COVID-19.”

Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai